Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (10): 1091-1096.
DOI: 10.19803/j.1672-8629.20220194
Previous Articles Next Articles
ZHAO Yifei, ZHAO Yan△, DONG Fang*, ZHENG Lijia, LI Dong, SONG Yana
Received:
2022-04-27
Online:
2022-10-15
Published:
2022-10-17
CLC Number:
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana. Introduction and inspiration of international medical device regulators forum patient registry guidelines[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20220194
[1] Agency for Healthcare Research and Quality. Registries for Evaluating Patient Outcomes: A User's Guide | Effective Health Care Program[EB/OL].(2007-05-16)[2022-08-01]. https://effectivehealthcare.ahrq.gov/products/registries-guide/research/. [2] International Medical Device Regulators Forum. International Medical Device Regulators Forum. Principles of International System of Registries Linked to Other Data Sources and Tools[EB/OL].(2016-09-30)[2022-08-01]. http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-160930-principles-system-registries.pdf. [3] ZHENG CS, LIU BY, FANG YG.Analysis of the research status of registry-based randomized controlled trials[J]. Journal of Traditional Chinese Medicine, 2020, 61(12): 1054-1058. [4] International Medical Device Regulators Forum. Methodological Principles in the Use of International Medical Device Registry Data | International Medical Device Regulators Forum[EB/OL](2017-03-16)[2022-08-01]. https://www.imdrf.org/documents/methodological-principles-use-international-medical-device-registry-data. [5] International Medical Device Regulators Forum. Tools for Assessing the Usability of Registries in Support of Regulatory Decision-Making[EB/OL].(2018-03-27)[2022-08-01]. http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-180327-usability-tools-n46.pdf. [6] U.S. Food & Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices[EB/OL].(2017-08-31)[2022-08-01]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices. [7] National Medical Product Administration. Announcement of Technical Guidelines of Real-world Data for Clinical Evaluation of Medical Devices (on Trial) (No. 77 of2020) [EB/OL]. (2020-11-26)[2022-08-01]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201126090030150.html. [8] BRINDIS RG, FITZGERALD S, ANDERSON HV, et al.The American college of cardiology-national cardiovascular data registry (ACC-NCDR): building a national clinical data repository[J]. J Am Coll Cardiol, 2001, 37(8): 2240. [9] ACHARYA T, SALISBURY AC, SPERTUS JA, et al.In-hospital outcomes of percutaneous coronary intervention in America's Safety Net: insights from the NCDR Cath-PCI Registry[J]. JACC Cardiovasc Interv, 2017, 10(15): 1475-1485. [10] GILL DRJ, PAGE RS, GRAVES SE, et al.The rate of 2nd revision for shoulder arthroplasty as analyzed by the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR)[J]. Acta Orthop, 2021, 92(3): 258-263. [11] PAXTON EW, INACIO M, SLIPCHENKO T, et al.The kaiser permanente national total joint replacement registry[J]. Perm J, 2008, 12(3): 12-16. [12] BLOEMHEUVEL EM, VAN STEENBERGEN LN, SWIERSTRA BA.Low revision rate of dual mobility cups after arthroplasty for acute hip fractures: report of 11,857 hip fractures in the Dutch Arthroplasty Register (2007-2019)[J]. Acta Orthop, 2020, 92(1): 35-38. [13] Cookies on GOV. UK. National Joint Registry Annual Report 2020[EB/OL].(2020-10-19)[2022-08-01]. https://data.gov.uk/dataset/a4e819dc-b08c-4e7b-a617-b60d1fb34b6f/national-joint-registry-annual-report-2020. [14] CARROLL JD, MACK MJ, VEMULAPALLI S, et al.STS-ACC TVT registry of transcatheter aortic valve replacement[J]. Ann Thorac Surg, 2021, 111(2): 701-722. [15] NOORI VJ, ARANSON NJ, MALAS M, et al.Risk factors and impact of postoperative hypotension after carotid artery stenting in the Vascular Quality Initiative[J]. J Vasc Surg, 2021, 73(3): 975-982. [16] CRONENWETT JL, KRAISS LW, CAMBRIA RP.The society for vascular surgery vascular quality initiative[J]. J Vasc Surg, 2012, 55(5): 1529-37. [17] Canadian Institute for Information. Hip and Knee Replacements in Canada: CJRR Annual Report,2020-2021[EB/OL].(2022-06-02)[2022-08-01]. https://www.cihi.ca/sites/default/files/document/hip-knee-replacements-in-canada-cjrr-annual-report-2020-2021-en.pdf. [18] BOHM ER, DUNBAR MJ, BOURNE R.The Canadian joint replacement registry-what have we learned?[J]. Acta Orthop, 2010, 81(1): 119-121. [19] BOURKE BM, BEILES CB, THOMSON I, et al.Development of the australasian vascular surgical Audit[J]. J Vasc Surg, 2012, 55: 164-170. [20] BEILES CB, WALKER S.Mortality after open aortic aneurysm surgery by Australasian surgeons trained in the endovascular era[J]. ANZ J Surg, 2016, 86(7-8): 544-548. [21] CARROLL JD, EDWARDS FH, MARINAC-DABIC D, et al.The STS-ACC transcatheter valve therapy national registry a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies[J]. Journal of the American College of Cardiology, 2013, 62(11): 1026-1034. [22] SEDRAKYAN A, PAXTON EW, PHILLIPS C, et al.The international consortium of orthopaedic registries: overview and summary[J]. J Bone Joint Surg Am, 2011, 93(3): 1-12. [23] BECK AW, SEDRAKYAN A, MAO J, et al.International consortium of vascular registries. variations in abdominal aortic aneurysm Care: A report from the international consortium of vascular registries[J]. Circulation, 2016, 134(24): 1948-1958. [24] Vascular Society. Vascular Society for Great Britain and Ireland[EB/OL].(2022-07-06)[2022-08-01]. https://www.vascularsociety.org.uk/default.aspx. [25] TAN J, CHENG LL, WANG W, et al.Real world study using observational designs: plan for patient registry study and development of registry database[J]. Chinese Journal of Evidence-Based Medicine, 2017, 17(12): 1365-1372. [26] TAN J, PENG XX, SHU XC, et al.Technical guidance for developing patient registry databases[J]. Chinese Journal of Evidence-Based Medicine, 2019, 19(7): 771-778. [27] ZHOU L, OUYANG WW, LI G, et al.Analysis of the current situation of registry studies in China[J]. Chinese Journal of Evidence-Based Medicine, 2019, 19(6): 702-707. [28] HUO Y, LIU ZP.Construction and prospection of percutaneous coronary intervention quality control system[J]. Tianjin Medical Journal, 2015, 43(8): 833-836. [29] YU Y, ZHAI W, LIN W, et al.Current status and analysis of overseas and domestic medical device registry study[J]. China Medical Device Information, 2021, 27(1):1-3, 167. [30] YAO HW, LI XW, CUI L, et al.Annual report of Chinese colorectal cancer surgery database in 2019: a nationwide registry study[J]. Chinese Journal of Practical Surgery, 2020, 40(1):106-110, 116. [31] ClinicalTrials.gov. A multi-center registry study: the follow-up the complications for trans-vaginal mesh surgery full text view[EB/OL].(2019-07-23)[2022-08-02]. https://clinicaltrials.gov/ct2/show/NCT04025047?term=mesh&recrs=a&cond=Pelvic+Organ+Prolapse&draw=2&rank=4. [32] Ministry of Industry and Information Technology, et al. Notice of ten departments on printing and distributing the 14th Five-year Plan for the Development of Medical Equipment Industry[EB/OL].(2021-12-21)[2022-08-02]. http://www.gov.cn/zhengce/zhengceku/2021-12/28/content_5664991.htm. [33] Gov. Opinions on deepening the reform of the review and approval system and encouraging the innovation of drugs and medical devices[EB/OL].(2017-10-08)[2022-08-02]. http://www.gov.cn/zhengce/2017-10/08/content_5230105.htm. [34] Gov. The 14th Five-Year National Plan on Drug Safety and High-quality Development Promoting[EB/OL].(2022-01-02)[2022-08-02]. http://www.gov.cn/xinwen/2022-01/02/content_5667258.htm. [35] WANG YJ, JING J, MENG X, et al.The third China national stroke registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics[J]. Stroke Vasc Neurol, 2019, 4(3): 158-164. [36] GU DC, ZHEN Z, ZHAO W, et al.Establishment of Chinese cardiovascular surgery registry database[J]. Chinese Circulation Jurnal, 2017, 232(10): 1010-1014. [37] State Administration for Market Regulation. Administrative measures for monitoring and reevaluation of adverse events of medical devices[EB/OL].(2018-08-13)[2022-08-02]. https://gkml.samr.gov.cn/nsjg/bgt/202106/t20210624_331375.html. [38] ZHANG L, JIA W, JI N, et al.Construction of the national brain tumor registry of China for better management and more efficient use of data: a protocol[J]. BMJ Open, 2021, 11(1): e040055. [39] U.S. Food and Drug Administration. Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment[EB/OL].(2005-03-22)[2022-08-02]. https://www.fda.gov/media/71546/download. |
[1] | ZHANG Qi, CHEN Min, ZHANG Shiqing. Conditional approval of medical devices in the United States and enlightenment [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010. |
[2] | ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang. Applicability of patient registry research to regulation of medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427. |
[3] | ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing. Advances in studies on post-market safety data sources and signal detection for medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240. |
[4] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[5] | SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong. Thoughts on constructing vigilance system of Chinese medical device in the new era [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701. |
[6] | TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei. Progress in the application of real-world data in post-market surveillance of medical devices [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238. |
[7] | TAN Jing, LIU Chunrong, HUANG Shiyao, GAO Pei, WANG Yang, LI Chen, HE Yong, YUAN Hong, WANG Wen, LI Ling, XIONG Yiquan, REN Yan, YAO Minghong, ZHAO Yan, DONG Fang, SHEN Chuanyong, SUN Xin. Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 13-17. |
[8] | ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling. Methods for risk trend analysis of EU post-marketing surveillance for medical devices [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82. |
[9] | MAO Zhenbin, LIU Shuyu. Implications of Regulatory Science for the Construction of Medical Device Vigilance Systems [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 601-605. |
[10] | ZHAO Yan, ZHAO Yifei△, ZHENG Lijia, DONG Fang. Medical Device Vigilance Systems in European Union [J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 566-569. |
[11] | ZHANG Shiqing, WANG Yingjun. Practice and Exploration of Uniformity about Medical Device Evaluation Criterion [J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1001-1003. |
[12] | JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei. Clinical Evaluation of Medical Devices Seen from International Coordination Documents [J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065. |
[13] | MENG Kangkang, SUN Nan, DONG Duo. Post-marketing Monitoring and Evaluation System in Japan [J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 944-948. |
[14] | ZHANG Shiqing, ZHANG Xingdong. Role of Standards in Medical Device Evaluation [J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 1-3. |
[15] | TIAN Chun-hua, LI Xin-ling, ZHOU Ran, XUE Bin, YANG Wei. Enlightenment of Japanese Drug Post-marketing Evaluation System to China [J]. Chinese Journal of Pharmacovigilance, 2017, 14(9): 527-529. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||